American Journal of Cardiology
Volume 101, Issue 12, Supplement , Pages S41-S50 , 16 June 2008

Review of the Evidence for the Clinical Utility of Lipoprotein-Associated Phospholipase A2 as a Cardiovascular Risk Marker

  • Marshall A. Corson, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, University of Washington, Seattle, Washington, USA
    • Corresponding Author InformationAddress for reprints: Marshall Corson, MD, Division of Cardiology, Department of Medicine, Harborview Medical Center, University of Washington School of Medicine Box 359748, Rm 2EH-64, 325 9th Avenue, Seattle, Washington 98104.
    • ,
  • Peter H. Jones

      Affiliations

    • Baylor Lipid and Atherosclerosis Clinic, Baylor College of Medicine, Houston, Texas, USA
    • ,
  • Michael H. Davidson, MD

      Affiliations

    • University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA
    • Radiant Research, Chicago, Illinois, USA.

References 

  1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421II-30–II-31
  2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  3. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511
  4. Garza CA, Montori VM, McConnell JP, Somers VK, Kullo IJ, Lopez-Jimenz F. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc. 2007;82:159–165
  5. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004;109:837–842
  6. Koenig W, Khuseyinova N, Löwel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany (MONICA-Augsburg). Circulation. 2004;110:1903–1908
  7. May HT, Horne BD, Anderson JL, Wolfert RL, Muhlestein JB, Renlund DG, et al. Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. Am Heart J. 2006;152:997–1003
  8. Macphee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J. 1999;338:479–487
  9. Lavi S, McConnell JP, Rihal CS, Prasad A, Mathew V, Lerman LO, et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation. 2007;115:2715–2721
  10. Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26:2523–2529
  11. Vickers KC, Maguire C, Wolfert RL, Insull W, Holvoet P, Morrisett J. Quantitation and distribution of lipoprotein-associated phospholipase A2 and oxidized low-density lipoprotein in atherosclerotic lesions of carotid endarterectomy tissues [abstract]. J Am Coll Cardiol. 2006;47(suppl A):346A
  12. Mannheim D, Herrmann J, Versari D, Gössl M, Meyer FB, McConnell JP, et al. Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaque. Stroke. 2008;39:1445–1448
  13. Hakkinen T, Luoma JS, Hiltunen MO, MacPhee CH, Milliner KJ, Patel L, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1999;19:2909–2917
  14. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657–671
  15. Tuczu EM, Kapadia SR, Tutar E, Ziada KM, Hobbs RE, McCarthy PM, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation. 2001;103:2705–2710
  16. Packard CJ, O'Reilly DS, Caslake MJ, McMahan AD, Ford I, Cooney J, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med. 2000;343:1148–1155
  17. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM. A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women. J Am Coll Cardiol. 2001;38:1302–1306
  18. Winkler K, Abletshauser C, Friedrich I, Hoffmann MM, Wieland H, März W. Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes. J Clin Endocrinol Metab. 2004;89:1153–1159
  19. Oei H-HS, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MMB, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischaemic stroke: the Rotterdam Study. Circulation. 2005;111:570–575
  20. Caslake MJ, Cooney J, Murray E, Bedford D, Robertson M, Nelson JJ, et al. Lipoprotein-associated phospholipase A2 as a risk factor for coronary vascular disease in the elderly (PROSPER). Stroke. 2008;In Press
  21. Jenny NS, Solomon C, Cushman M, Nelson JJ, Tracy RP, Psaty BM, et al. Lipoprotein-associated phospholipase A2 and cardiovascular disease: results from the Cardiovascular Health Study [abstract]. Circulation. 2006;113:E-332
  22. Daniels LB, Barrett-Connor E, Sarno M, Laughlin GA, Bettencourt R, Wolfert RL. Lipoprotein-associated phospholipase A2 (Lp-PLA2) independently predicts incident coronary heart disease (CHD) in an apparently healthy older population: the Rancho Bernardo Study. J AM Coll Cardiol. 2008;51:913–919
  23. Persson M, Hedblad B, Nelson JJ, Berglund G. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol. 2007;27:1411–1416
  24. Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol. 2007;27:1788–1795
  25. Blankenberg S, Stengel D, Rupprecht HJ, Bickel C, Meyer J, Cambien F, et al. Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. J Lipid Res. 2003;44:1381–1386
  26. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J. 2005;26:137–144
  27. Winkler K, Winkelmann BR, Scharnagl H, Hoffman MM, Grawitz AB, Nauck M, et al. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors. Circulation. 2005;111:980–987
  28. Khuseyinova N, Imhof A, Rothenbacher D, Trischler G, Kuelb S, Scharnagl H, et al. Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis (HELICOR). Atherosclerosis. 2005;182:181–188
  29. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function and hemodynamic stress (KAROLA). Arterioscler Thromb Vasc Biol. 2006;26:1586–1593
  30. Corsetti JP, Rainwater DL, Moss AJ, Zareba W, Sparks CE. High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients. Clin Chem. 2006;52:1331–1338
  31. Gerber Y, McConnell JP, Jaffe AS, Weston SA, Killian JM, Roger VL. Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. Arterioscler Thromb Vasc Biol. 2006;26:2517–2522
  32. O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, et al. Lp-PLA2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT TIMI–22 (PRavastatin Or atorVastatin Evaluation and Infection-Thrombolysis in Myocardial Infarction) trial. Circulation. 2006;113:1745–1752
  33. Oldgren J, James SK, Siegbahn A, Wallentin L. Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. Eur Heart J. 2007;28:699–704
  34. Mockel M, Muller R, Vollert JO, Muller C, Danne O, Gareis R, et al. Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach (The North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II)). Clin Res Cardiol. 2007;96:604–612
  35. Sabatine MS, Morrow DA, O'Donoghue M, Jablonski KA, Rice MM, Solomon S, et al. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol. 2007;27:2463–2469
  36. Robins SJ, Collins D, Nelson JJ, Bloomfield HE, Asztalos BF. Cardiovascular Events With Increased Lipoprotein-Associated Phospholipase A2 and Low High-Density Lipoprotein-Cholesterol (The Veterans Affairs HDL Intervention Trial). Anterioscler Thromb Vasc Biol. 2008;28:DOI: 10.1161/ATVBAHA.107.160739
  37. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Chambless LE, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2005;165:2479–2484
  38. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke (NOMAS). Arch Intern Med. 2006;166:2073–2080
  39. Hatoum IJ, Nelson JJ, Rexrode K, Manson J, Rimm EB. Lipoprotein-associated phospholipase A2 and myocardial infarction in women. Circulation. 2007;116:II-818;Abstract 3605
  40. Furie KM, Parides MK, Greer DM, Camargo ECS, Singhal AB, Lederer M, et al Lipoprotein-associated phospholipase A2 activity predicts early stroke recurrence [abstract]. Stroke. 2007;382s:458
  41. Wassertheil-Smoller S, Kooperberg C, McGinn AP, Kaplan RC, Berger JS. Lipoprotein-associated phospholipase A2 and risk of ischemic stroke in postmenopausal women: the Women's Health Initiative Observational Study [abstract]. Circulation. 2007;115:e222
  42. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–1158
  43. Iribarren C, Gross MD, Darbinian JA, Jacobs DR, Sidney S, Loria CM. Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study. Arterioscler Thromb Vasc Biol. 2005;25:216–221
  44. Kardys I, Oei HH, Hofman A, Oudkerk M, Witteman JC. Lipoprotein-associated phospholipase A2 and coronary calcification: the Rotterdam Coronary Calcification Study. Atherosclerosis. 2006;191:377–383
  45. Winkler K, Hoffmann MM, Winkelmann BR, Friedrich I, Schäfer G, Seelhorst U, et al. Lipoprotein-associated phospholipase A2 predicts 5-year mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen Risk and Cardiovascular Health Study). Clin Chem. 2007;53:1440–1447
  46. Folsom AR, Chambless LE, Ballantyne CM, Coresh J, Heiss G, Wu KK, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the Atherosclerosis Risk in Communities study. Arch Intern Med. 2006;166:1368–1373
  47. Ballantyne C, Nambi V, Chambless L, Hu Y, Coresh J, Ni J, Folsom A, Sharrett A, Boerwinkle E, Hoogeveen R. Inflammatory biomarkers Lp-PLA2 and CRP for prediction of first ischemic stroke. Stroke, In Press.
  48. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007;115:928–935
  49. Wolfert RL, Kim NW, Selby RG, Sarno MJ, Warnick RG, Sudhir K. Biological variability and specificity of lipoprotein-associated phospholipase A2 (Lp-PLA2), a novel marker of cardiovascular risk [abstract]. Circulation. 2004;110(suppl 3):309
  50. Khuseyinova N, Greven S, Rueckerl R, Trischler G, Loewel H, Peters A, et al. Variability of serial Lp-PLA2 measurements in post-myocardial infarction patients: results from the AIRGENE Study Center Augsburg. Clin Chem. 2007;54:124–130
  51. McConnell JP, Hoefner DM. Lipoprotein-associated phospholipase A2 [review]. Clin Lab Med. 2006;26:679–697
  52. McLaughlin TM, Abbasi F, Wolfert R, Lamendola C, Reaven G, Reaven P. Lipoprotein-associated phospholipase A2 is not increased in association with insulin resistance [abstract]. Arterioscler Thromb Vasc Biol. 2004;24:E-67
  53. Carlquist JF, Muhlestein JB, Anderson JL. Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Rev Mol Diagn. 2007;7:511–517
  54. Lanman RB, Wolfert RL, Fleming JK, Jaffe AS, Roberts WL, Warnick GR, et al. Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults. Prev Cardiol. 2006;9:138–143

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9149(08)00715-7

doi: 10.1016/j.amjcard.2008.04.018

American Journal of Cardiology
Volume 101, Issue 12, Supplement , Pages S41-S50 , 16 June 2008

Article Tools

* Image Usage & Resolution